Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
The effectiveness of platinum drugs in the treatment of cancer is hindered by intrinsic and acquired resistance. The cause of clinical resistance to platinum compounds is still unknown. In an attempt to identify new cellular mechanisms of cisplatin resistance, a one-step cisplatin-selection procedure was used to generate resistant sublines of the platinum sensitive A2780 ovarian cancer cell line. In the present study we selected an A2780 subline, A2780-Pt, that has a significantly reduced ability to accumulate cisplatin (36% of the parent A2780 cell line) and consequently shows a clear cisplatin-resistant phenotype (resistance factor, i.e., RF: 8.6). The A2780-Pt cell line was specifically cross-resistant to carboplatin (RF: 12.0), tetraplatin (RF: 8.1) and oxaliplatin (RF: 6.1) which was associated with a reduced cellular platinum accumulation (50%, 54% and 58% of A2780, respectively). No cross-resistance was found for a variety of other anticancer agents. Further experiments to determine the cause of the platinum resistance of the A2780-Pt cell line revealed that: (1) impaired cellular platinum accumulation could not be attributed to aberrant expression of MRP2 (ABCC2), CTR1 (SLC31A1), ATP7A or ATP7B, (2) resistance was not associated with platinum inactivation by metallothionein and glutathione, (3) the platinum efflux rate was similar to that of A2780, (4) the defect in cellular accumulation and the resistance could be overcome by treatment with cisplatin nanocapsules, consistent with impaired influx, and (5) the defect in accumulation is specific for platinum compounds in the cis-configuration, since A2780-Pt cells did not show reduced accumulation of transplatin. This specificity suggests that not passive diffusion but an inward transporter is impaired in A2780-Pt. In conclusion, we generated an A2780 subline that showed a uniquely stable platinum resistance phenotype, which could theoretically be caused by an impaired inward transporter specific for cis-configurated platinum compounds.
Helleman
Jozien
J
Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Burger
Herman
H
Hamelers
Irene H L
IH
Boersma
Antonius W M
AW
de Kroon
Anton I P M
AI
Stoter
Gerrit
G
Nooter
Kees
K
D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D016190:Carboplatin / Q000493:pharmacokinetics; D027682:Cation Transport Proteins / Q000502:physiology*; D002945:Cisplatin / Q000493:pharmacokinetics*; D019008:Drug Resistance, Neoplasm; D005260:Female; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D000089762:Multidrug Resistance-Associated Protein 2; D036103:Nanotechnology; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D009944:Organoplatinum Compounds / Q000493:pharmacokinetics; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000077150:Oxaliplatin; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
C000715087:ABCC2 protein, human; D000970:Antineoplastic Agents; D027682:Cation Transport Proteins; D000089762:Multidrug Resistance-Associated Protein 2; D009363:Neoplasm Proteins; D009944:Organoplatinum Compounds; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D000077150:Oxaliplatin; C034697:transplatin; D016190:Carboplatin; D005978:Glutathione; D002945:Cisplatin; C049777:ormaplatin